India ruling on cancer drug to be challenged

Order forcing Bayer to license its product to local company has huge repercussions for pharmaceutical giants.



    A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.

    This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.

    This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.

    Prerna Suri reports from New Delhi.

    SOURCE: Al Jazeera


    YOU MIGHT ALSO LIKE

    Interactive: Take a tour through divided Jerusalem

    Interactive: Take a tour through divided Jerusalem

    Take a tour through East and West Jerusalem to see the difference in quality of life for Israelis and Palestinians.

    Stories from the sex trade

    Stories from the sex trade

    Dutch sex workers, pimps and johns share their stories.

    Inside the world of India's booming fertility industry

    Inside the world of India's booming fertility industry

    As the stigma associated with being childless persists, some elderly women in India risk it all to become mothers.